CYP2C19 Poor Metabolizer Is Associated with Clinical Outcome of Clopidogrel Therapy in Acute Myocardial Infarction but Not Stable Angina Running title: Kim et al.; CYP2C19 PM on Clopidogrel in AMI and Stable Angina
نویسندگان
چکیده
Dept of Pharmacology & PharmacoGenomics Research Center, Inje University College of Medicine; Dept of Clinical Pharmacology, Inje University Busan Paik Hospital, Busan, Cardiovascular Center & Cardiology Division, Seoul St. Mary’s Hospital & College of Medicine, The Catholic University of Korea, Seoul; Dept of Cardiology, Catholic University Uijeongbu St. Mary’s Hospital, Uijeongbu; Dept of Cardiology, Catholic University Daejeon St. Mary’s Hospital, Daejeon; Dept of Cardiology, Catholic University Yeouido St. Mary’s Hospital, Seoul, Republic of Korea *contributed equally
منابع مشابه
CYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable angina.
BACKGROUND More intensive platelet suppression is required in patients with acute myocardial infarction (AMI) than in those with stable angina because of differential platelet activation between AMI and stable angina. In this context, CYP2C19 genotype leading to reduced active metabolite formation may profoundly affect the clinical outcome of clopidogrel therapy in patients with AMI compared wi...
متن کاملCytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome
BACKGROUND The cytochrome P450 (CYP450) 2C19 681 genotypes affect the antiplatelet activity of clopidogrel. We investigated the correlation of CYP 2C19 681G > A mutation with clopidogrel resistance (CR). Additionally, we studied the effect of CR on clinical prognosis of patients with acute coronary syndrome (ACS). METHODS One hundred ten ACS patients undergoing percutaneous coronary intervent...
متن کاملCost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention
BACKGROUND Prasugrel is recommended over clopidogrel in poor/intermediate CYP2C19 metabolizers with acute coronary syndrome (ACS) and planned percutaneous coronary intervention (PCI), reducing the risk of ischemic events. CYP2C19 genetic testing can guide antiplatelet therapy in ACS patients. OBJECTIVE The purpose of this study was to evaluate the cost-utility of genotype-guided treatment, co...
متن کاملGenetic Polymorphisms of CYP2C19 and Resistance to Clopidogrel Therapy among Iranian Patients Suffering from Ischemic Heart Disease
Background: Clopidogrel is a standout amongst the most ordinarily recommended medications to avoid ischemic occasions taking after coronary disorder or stant position. However, impaired responses the therapy as well as resistance to the therapy have also been reported. Genetic variants play an important role in clopidogrel biotransformation of its active metabolite that may subsequently influen...
متن کاملEffect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin.
BACKGROUND As compared with whites, East Asians more often carry the cytochrome P450 (CYP) 2C19 loss-of-function (LOF) allele with the CYP2C19*3 variant. The influence of the CYP2C19 LOF alleles (*2 and *3) on clopidogrel response and clinical outcomes in East Asians with acute myocardial infarction (AMI) has not been reported. We sought to evaluate the effect of the CYP2C19 variants on clopido...
متن کامل